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Background: Heat shock protein 70, a stress protein, has been implicated in tumor progression. However, its role in
nasopharyngeal carcinoma (NPC) progression has not yet been clearly investigated.
Methods: Immunohistochemistry (IHC) was employed to examine the expression patterns of Hsp70, human
leukocyte antigen –A (HLA-A) in NPC tissue samples.
Results: The expression of Hsp70 exhibited different spatial patterns among nuclear, membrane and cytoplasm in
507 NPC tumor tissues. Kaplan-Meier survival analysis demonstrated that different Hsp70 expression patterns are
correlated with different patient outcomes. High membranal and cytoplasmic levels of Hsp70 predicted good
survival of patients. In contrast, high nuclear abundance of Hsp70 correlated with poor survival. Moreover, the
membranal and cytoplasmic levels of Hsp70 were positively correlated with levels of the MHC I molecule HLA-A.
Conclusions: Different Hsp70 expression patterns had distinct predictive values. The different spatial abundance of
Hsp70 may imply its important role in NPC development and provide insight for the development of novel
therapeutic strategies involving immunotherapy for NPC.
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Nasopharyngeal carcinoma (NPC) is a leading lethal ma-
lignancy with a high prevalence in Southeast Asia, espe-
cially in the Guangdong, Guangxi and Hong Kong areas
in Southern China [1,2]. The incidence rate of NPC is
25–40 cases per 100,000 person-years in the Cantonese
region of Southern China [3]. Most NPC tumor cells are
poorly differentiated or undifferentiated and have high
tendency to invade adjacent regions and metastasize to
neck lymph nodes. Radiotherapy (RT) and concurrent
chemoradiotherapy (CCRT) are standard treatments for
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reproduction in any medium, provided the orTherapeutic strategies have been studied aiming to im-
prove the survival rate for advanced NPC. Recently, novel
therapies based on molecular targets and neoadjuvant
chemotherapy (NAC) followed by RT of NPC were prom-
ising for advanced lesions [7,8], though need to be vali-
dated in more trials. Conventional TNM staging has a
strong prognostic implication for NPC [9]; and patients at
early-stage are almost curable under RT, however, the
prognosis remains poor in a significant number of patients
with late-stage NPC [10] . Local failure and distant metas-
tasis are major issues resulting in poor outcomes in NPC
patients at advanced-stage [11]. Therefore, it is of clinical
value to identify factors that allow for an early diagnosis
and the prediction of prognosis and to discover novel
therapeutic strategies.
During tumor development, cancer cells frequently en-
counter a variety of cytotoxic conditions, such as hyp-
oxia and local hyperthermia [12,13]. Heat shock proteins. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of nasopharyngeal carcinoma
patients (n = 507)






Median (range) 46 (19–78)











Median (range) 68 (3–114)







SD, standard deviation; WHO, World Health Organization; NKUC, non-
keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated
carcinoma; KSCC, keratinizing squamous cell carcinoma.
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iety of stresses, such as hyperthermia, and play pivotal
roles in tumor cell survival after exposure to unfavorable
insults [14]. Among the HSPs, Hsp70 mediates the pro-
tection of tumor cells from stress-induced lethal damage
by interfering apoptotic pathways [15,16]. Furthermore,
high cytosolic levels of Hsp70 are frequently associated
with a negative clinical outcome and a higher frequency
of metastasis [17]. Studies on NPC have shown that high
serum levels of Hsp70 are strongly associated with T
classification, metastasis and mortality, indicating a poor
prognosis [18,19].
HSPs also have important roles in the immune system
as carriers of tumor antigens [20,21]. Hsp70-
chaperoned peptides derived from the cytosol of human
tumors can activate a classical protective T-cell mediated
immune response [22], which involves the uptake of
HSP-peptide complexes by antigen-presenting cells
(APCs) and the subsequent cross-presentation on MHC
class I molecules to specific CD8+ T-cell populations
[22] . In a study of NPC, the reconstituted complex with
mycobacterial Hsp70 and EBV LMP2A-derived peptides
has been shown with ability to elicit peptide-specific
cytotoxic T-lymphocyte responses and anti-tumor im-
mune cells [23]. Hsp70, therefore, appears to play dual
roles in the progression of tumors. To date, however, the
expression dynamics of Hsp70 tissues and the relevance
to the clinicopathologic and prognostic significance have
not been clearly investigated in NPC.
Here, we first examined Hsp70 expression patterns
with immunohistochemical (IHC) staining of 507 paraf-
fin-embedded NPC tumor tissues. Secondly, we analyzed
the correlation between the Hsp70 expression level and
the clinical factors and outcomes for NPC patients. Fur-
thermore, we evaluated the possible role of Hsp70 in the
progression of NPC tumors.
Materials and methods
Patients and clinical tissue samples
In this study, 507 NPC specimens were collected at the
Sun Yat-Sen University Cancer Center, Guangzhou,
China, between January 2001 and December 2003. The
cases were selected based on the following criteria:
pathologically confirmed diagnosis of nasopharyngeal
carcinoma with biopsy specimens available for tissue
microarray (TMA) construction, no previous malignant
disease or second primary tumor and no history of
radiotherapy, chemotherapy or surgical treatment. All
selected samples comprised at least 70% carcinoma tis-
sue as determined by frozen section examination. The
patient characteristics are shown in Table 1. The clinical
stage was defined according to the 1992 NPC staging
system of China [24]. All patients were treated with
standard curative radiotherapy with or withoutchemotherapy. The follow-up period was defined as the
time from diagnosis to the date of death or to the time
of censure if the patient was still alive. Disease progres-
sion was defined as progressive disease after primary
treatment or recurrence (local progression) and/or the
development of new distant metastases (distant progres-
sion). The Institute Research Medical Ethics Committee
of Sun Yat-Sen University granted approval for this
study.Tissue microarray construction
The paraffin-embedded specimens were included in the
previously constructed tissue microarray (TMA) and the
procedures for the TMA construction have been
described previously [25]. Briefly, the paraffin-embedded
tissue blocks and the corresponding histological H&E-
stained slides were overlaid for tissue TMA sampling.
Duplicate 1.0 mm diameter cylinders were punched
from representative tumor areas of an individual donor
tissue block and re-embedded into a recipient paraffin
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ment (Beecher Instruments, Silver Spring, MD).Immunohistochemistry (IHC) and evaluation
IHC was performed to examine the Hsp70 and HLA-A
expression in nasopharyngeal carcinoma tissues, by
using primary antibodies against Hsp70 (1:200 dilution;
sc-24, Santa Cruz, USA) and HLA-A (1:300 dilution;
sc-23446, Santa Cruz, USA), and according to the
previous procedures [25]. The IHC results were evaluated
and scored independently by three pathologists without
knowledge of the patient’s clinicopathological outcomes.
A semi-quantitative estimate was made using a composite
score obtained by adding the intensity of the staining and
the relative abundance of positive cells. The intensity was
graded as 0 (negative), 1 (weakly positive), 2 (moderately
positive) or 3 (strongly positive). The abundance of posi-
tive cells was graded from 0 to 4 (0, < 5% positive cells; 1,
5–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%). The patholo-
gists were in agreement for approximately 82.5% of the
cases, which demonstrated that this scoring method was
highly reproducible. If at least 2 scores were in agreement,
the consensus value was selected. If all three pathologists
proposed different results, the pathologists reached a
consensus.Selection of cutoff score
Receiver operating characteristic (ROC) curve analysis
was performed to determine the cutoff score for a “high
expression” designation with the 0,1-criterion implemen-
ted in SPSS software [25]. First, the clinicopathological
characteristics were dichotomized as following groups: T
classification (T1-T2 versus T3-T4), N classification (N0
versus N1-N3), clinical stage (I-II versus III-IV), cancer
progression (Yes versus No) and survival status (death
due to NPC versus censored). Second, the expression
scores for Hsp70 were trained in the ROC analysis. The
cutoff score is the point on the curve that has both max-
imum sensitivity and specificity [25].Statistical analyses
Statistical analyses were performed with the SPSS statis-
tical software package (standard version 16.0; SPSS,
Chicago, IL). Associations between the Hsp70 expression
and clinicopathological parameters were assessed using a
Chi-Square test. Associations between the Hsp70 expres-
sion patterns and HLA-A levels were examined with
Pearson correlation and independent t-test. Survival
curves were plotted by Kaplan-Meier analysis and com-
pared by the log-rank test. The Cox proportional
hazards regression model was employed to identify inde-




Among the 507 patients, 381 (75.1%) were male, and the
median age was 46 years (ranging 17–78 years). One hun-
dred and twenty-nine tumors (25.4%) were diagnosed as
non-keratinizing differentiated carcinoma (NKDC), and
364 tumors (71.8%) were diagnosed as non-keratinizing
undifferentiated carcinoma (NKUC), 13 tumors (2.6%)
were categorized as keratinizing squamous cell carcinoma
(KSCC). One hundred and forty patients (27.7%) were at
stages I or II, and 367 patients (72.3%) were at stages III
or IV. The median follow-up time was 60.81 months (ran-
ging 3–114 months). Of the total number of patients, 166
(32.6%) died, and 197 (38.9%) experienced disease pro-
gression during the five-year follow-up. The detailed clin-
ical information is shown in Table 1.
Different expression patterns of Hsp70 in NPC
A total of 507 NPC cases with five-year follow-up infor-
mation were examined for the Hsp70 expression. Spe-
cific Hsp70 staining was detected in the tumor nest cells
but not in the stroma. Interestingly, different staining
patterns of Hsp70 were observed in NPC tumor tissues
(Figure 1 A, B), with spatial difference among nuclear,
membrane and cytoplasm. Therefore, the membranal
and the cytoplasmic expression or nuclear abundance of
Hsp70 were separately scored and evaluated for their
predictive values in NPC.
Selection of the cutoff score for high expression of Hsp70
ROC curve analysis showed that both extra-nucleic and
nucleic abundance of Hsp70 have some sort of predict-
ive values in NPC, with maximum area under curve
(AUC) reaching 0.620 and 0.577 for Hsp70 abundance
in the two locations, respectively (Figure 2E and J, black
arrowed). The points in curves with maximum specifi-
city and sensitivity were treated as cutoff points for high
expression of Hsp70. For survival analysis the cutoff
score for membranal and cytoplasmic expression of
Hsp70 was 3.5, and the cutoff score for the nuclear ex-
pression of Hsp70 was defined as 4.5 (Table 2). As a re-
sult, tumors designated as low expression of Hsp70 are
those with the scores below or equal to the cutoff score,
while tumors of high expression are those with scores
above the cutoff score.
Association of Hsp70 expression patterns with
clinicopathologic features
High membranal and cytoplasmic expression levels of
Hsp70 were detected in 226/507 (44.6%) NPC tissues,
and high nuclear abundance of Hsp70 were observed in
Figure 1 Different expression patterns of Hsp70 in NPC tumor tissues. A, Low and high expression levels of Hsp70 in the membrane and
cytoplasm in the TMA are shown under both low and high magnification. B, Low and high levels of Hsp70 nuclear abundance in the TMA are
shown under both low and high magnification. Scale bars, 100 μm.
Cai et al. Journal of Translational Medicine 2012, 10:96 Page 4 of 10
http://www.translational-medicine.com/content/10/1/96137/507 (27.1%) NPC tissues. The frequencies of differ-
ent Hsp70 expression patterns with respect to several
clinicopathologic features are detailed in Table 3. Inter-
estingly, we found that high membranal and cytoplasmic
expression levels of Hsp70 were significantly negativelyFigure 2 Selection of the cutoff scores. Receiver operating characteristic
designation of “high expression” of Hsp70 with membranal, cytoplasmic or
Hsp70 membranal and cytoplasmic staining were plotted: (A) T classificatio
(D) Cancer progression (P <0.001); (E) Survival status (P <0.001). The sensit
plotted: (F) T classification (P =0.964); (G) N classification (P =0.97); (H) Clinic
(P =0.005)..correlated with tumor T classification, recurrence or me-
tastasis and advanced clinical stage (P< 0.01, Table 3),
but no significant association was observed between
Hsp70 membranal and cytoplasmic expression levels
and other clinicopathologic features such as sex, age andcurve analysis was employed to determine the cutoff score for the
nuclear staining. The sensitivity and specificity for each outcome of
n (P =0.002); (B) N classification (P =0.029); (C) Clinical stage (P =0.029);
ivity and specificity for each outcome of Hsp70 nuclear staining were
al stage (P =0.99); (I) Cancer progression (P =0.009); (J) Survival status
Table 2 The corresponding cutoff score of Hsp70
expression patterns for each clinicopathological feature





Cutoff score P value Cutoff score P value
T classification 3.5 0.002 5.5 0.964
N classification 1 0.029 3.5 0.97
Clinical stage 3.5 0.029 5.5 0.99
Cancer progression 1 <0.001 3.5 0.009
Survival status 3.5 <0.001 4.5 0.005
Hsp70, heat shock protein 70; ROC, receiver operating characteristic.
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abundance of nucleic Hsp70 was positively correlated
with tumor recurrence or metastasis (P< 0.05, Table 3),
but not with other clinicopathologic features such as
tumor T and N classification, sex, age and clinical stage
(P> 0.05, Table 3).
Association between the Hsp70 expression pattern and
survival
Due to the finding that the expression of Hsp70 was cor-
related with recurrence or metastasis, its correlation
with survival was examined. The 5-year overall survival
rate of the 507 NPC patients was 66.18%. The low and
high Hsp70 expression groups were divided by the cutoff
value as previously reported [25,26]. For these 507 NPCTable 3 Association of different Hsp70 expression patterns an
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III + IV 218 150
Hsp70, heat shock protein 70.patients, Kaplan-Meier and log-rank test analyses indi-
cated that patients with high Hsp70 membranal and
cytoplasmic expression levels had a significantly better
overall survival (OS; 5-year survival rates, 76.1% vs.
60.1%, P= 0.001, Figure 3A) and disease-free survival
(DFS; 5-year survival rates, 68.6% vs. 55.2%, P= 0.001,
Figure 3B) than patients with low Hsp70 expression
levels. Further stratification analysis by clinical stage
revealed that the Hsp70 membranal and cytoplasmic ex-
pression levels were not related to OS and DFS in the
early stages (Additional file 1: Figure S1A and B); how-
ever, for the patients at late-stage, high membranal and
cytoplasmic expression levels of Hsp70 were correlated
with improved OS (5-year survival rates, 66.7% vs.
52.3%, P= 0.006, Additional file 1: Figure S1C) and DFS
(5-year survival rates, 61.3% vs. 47.7%, P = 0.007,
Additional file 1: Figure S1D).
Moreover, the correlation between Hsp70 abundance
in the nuclei and survival was tested. Surprisingly, we
found that high nuclear abundance of Hsp70 correlated
with worse OS (5-year survival rates, 57.7% vs. 70.8%,
P= 0.001, Figure 3C) and DFS (5-year survival rates,
52.6% vs. 64.3%, P= 0.005, Figure 3D) than did low levels
of nuclear abundance of Hsp70. Subsequent stratifica-
tion analysis according to clinical stages revealed that
the nucleic abundance of Hsp70 is consistently corre-
lated with worse OS (5-year survival rates, 47% vs.
62.3%, P= 0.001, Additional file 2: Figure S2C) and DFSd clinicopathological characteristics in NPC patients
ing P
value























Figure 3 The association of different Hsp70 expression patterns with NPC patient survival. TMA analyses of a cohort of 507 NPC patients
diagnosed at M0 were conducted. A and B, high Hsp70 membranal and cytoplasmic expression levels were significantly positively associated
with overall survival (OS, P= 0.001) and disease-free survival (DFS, P= 0.001) in all NPC patients. C and D, high Hsp70 nuclear abundance were
significantly negatively associated with overall survival (OS, P= 0.001) and disease-free survival (DFS, P= 0.005) in NPC patients.
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file 2: Figure S2D); however, no correlation was found for
sample in the early stages (Additional file 2: Figure 2A and
B).
Association between clinicopathologic features, Hsp70
expression patterns and NPC patient survival: univariate
and multivariate survival analyses
To confirm the representative of the present NPC co-
hort, we tested the associations of some well-known
prognostic indicators with survival. The univariate Cox
proportional hazard regression analysis showed that the
clinicopathologic parameters including T classification,
N classification, recurrence or metastasis, and clinical
stage are each significantly associated with survival(P< 0.001; Table 4), which is consistent with the previ-
ous findings. Moreover, the assessment of NPC patient
survival revealed that high membranal and cytoplasmic
expression levels of Hsp70 were significantly correlated
with improved overall survival (P< 0.001; Table 4),
whereas high nuclear abundance of Hsp70 were signifi-
cantly correlated with poor overall survival (P= 0.001,
Table 4). In addition, the age was also associated with
survival (P= 0.002).
Independency tests were carried out among the prog-
nostic factors, including the different expression patterns
of Hsp70 and other significant clinicopathologic features
(age, T classification, N classification, distant metastasis
and clinical stage), under a multivariate Cox propor-
tional hazards regression analysis (Table 4). We found
Table 4 Univariate and multivariate Cox regression analyses of different prognostic variables for NPC patients
Variable Subset Hazard ratio (95%) CI P value
Univariate analysis (n = 507)
Hsp70 membranal and cytoplasmic staining low vs. high 0.540 (0.390-0.747) <0.001
Hsp70 nucleus staining low vs. high 1.708 (1.241-2.351) 0.001
Age <46 vs. >= 46 1.644 (1.202-2.249) 0.002
Sex male vs. female 0.827 (0.574-1.192) 0.308
T stage T1 + T2 vs. T3 + T4 3.149 (2.159-4.594) <0.001
N stage N0 vs. N1 +N2+N3 2.474 (1.592-3.846) <0.001
Recurrence or metastasis No vs. Yes 548.914 (76.728-3.927E3) <0.001
Clinical stage I + II vs. III + IV 6.034 (3.352-10.862) <0.001
Multivariate analysis (n = 507)
Hsp70 cytoplasmic and membranal staining low vs. high 0.529 (0.360-0.778) 0.001
Hsp70 nuclear staining low vs. high 2.601 (1.785-3.789) 6.41E-07
Clinical stage I + II vs. III + IV 3.641 (1.623-8.170) 0.002
CI, confidence interval; WHO, World Health Organization; Hsp70, heat shock protein 70.
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of Hsp70 were independent favorable factors for overall
patient survival (hazard ratio: 0.529; 95% confidence
interval: 0.360–0.778; P= 0.001), whereas high nuclear
levels of Hsp70 were an independent risk factor for over-
all patient survival (hazards ratio: 2.601; 95% confidence
interval: 1.785–3.789; P< 0.001). Among the other vari-
ables, clinical stage was also found to be an independent
prognostic predictor of overall survival (Table 4).
Correlation between the Hsp70 abundance and the
expression of HLA-A
In light of the involvement of Hsp70 in the antigen presen-
tation process, which HLA-A plays important role, we fur-
ther investigated the correlation between its abundance and
HLA-A expression. The results showed a markedly positiveFigure 4 Correlation between expression levels of Hsp70 and the lev
tissue were subjected to IHC staining with antibodies against Hsp70 and H
in the tumor tissue in case 1 were accompanied by an elevated level of HL
of Hsp70 in the tumor tissue of case 2 were accompanied by a low level o
membranal and cytoplasmic expression levels of Hsp70, an average HLA-A
higher than that (2.81) of the 281 NPCs with low expression levels of Hsp7correlation between the membranal and cytoplasmic ex-
pression level of Hsp70 and the expression of HLA-A in
NPC tissues (Figure 4A) (Pearson Correlation=0.255). In
the 226 NPC samples with high expression of membranal
and cytoplasmic Hsp70, the average HLA-A score was 3.82,
which was significantly higher than that (2.81) found in the
remaining 281 NPCs with low expression of membranal
and cytoplasmic Hsp70 (P< 0.001, independent sample t-
test; Figure 4B). On the other hand, although low expres-
sion of HLA-A was found in NPC tumors with abundant
nucleic Hsp70 (Pearson Correlation=−0.145), the correl-
ation didn’t reach a statistically significance (p=0.092).
Discussion
As a member of the HSP family, Hsp70 has been consid-
ered as cancer relevant protein. On one hand, its highel of HLA-A in NPC tissues. A, continuous sections of human NPC
LA-A. The high membranal and cytoplasmic expression levels of Hsp70
A-A. Conversely, the low membranal and cytoplasmic expression levels
f HLA-A. Scale bars = 100 μm. B, in 226 NPC cases with high
score was 3.82 (right column), an average score that was significantly
0 (left column, P< 0.001, independent sample t-test).
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such as breast cancer [27], lung cancer [28], oral squa-
mous cell carcinoma [29] and prostate cancer [30]; and
moreover, its overexpression has been correlated with
poor prognosis and resistance to therapy [27-30]. These
suggest that Hsp70 might promote somehow tumor de-
velopment. On the other hand, previous studies have
shown that Hsp70 acts as chaperone for presenting
tumor antigens to activate immune response [20,21],
and mediate anti-cancer immunity [31], suggesting the
opposite role of Hsp70 to tumor development. The
mechanism underlying the dual roles of Hsp70 to
tumorigenesis is still unclear.
In the present study, the expression of Hsp70 was
determined by IHC in a large cohort of NPC tissues
using a NPC-TMA with follow-up data. Among the 507
patients, we noted distinct nuclear, membranal and cyto-
plasmic localization of Hsp70 in NPC tissues. Interest-
ingly, we observed that distinct Hsp70 expression patterns
correlated with different clinical outcomes. High membra-
nal and cytoplasmic expression levels of Hsp70 predicted
an improved survival rate, whereas high nuclear abun-
dance of Hsp70 was correlated with a poor survival rate.
These findings suggest that Hsp70 might be a favorable
prognostic indicator, which could be used in the search of
novel treatment to improve survival for the patient with
poor predicted outcome.
More importantly, further correlation analyses revealed
that high membranal and cytoplasmic expression levels of
Hsp70 in NPCs were negatively associated with tumor T
classification, N classification, recurrence and metastasis,
advanced clinical stage and histological type. In contrast,
high nuclear abundance of Hsp70 was positively corre-
lated with tumor recurrence, metastasis and histological
type. These results suggested that membranal and cyto-
plasmic Hsp70 might play an anti-tumor role, whereas nu-
clear Hsp70 may provide a selective advantage in the NPC
tumorigenic processes.
NPC is a malignancy widely known as Epstein-Barr virus
(EBV)-related, and thus many immune-related genes have
been examined for the association with NPC development.
Among them, human leukocyte antigen (HLA) has been
extensively studied, considering the capability of HLA to
present antigen to cytotoxic T cells and, thus, trigger the
host immune response against viral infection. Genetic stud-
ies have shown that some HLA alleles such as HLA-
A*0203 and HLA-A*0207 are risk alleles while HLA-
A*1101 is a protective allele for NPC [32]. Moreover, the
genome-wide expression profiling study showed that the
expression of MHC class I molecules were inhibited by
EBV genes in NPC tumors [33]. HLA restricted EBV var-
iants, which lose T-cell epitopes have been demonstrated in
NPC [34,35]. In addition, loss of HLA locus in NPC tumor
genome was observed (unpublished data). These findingsconsistently support the contribution of HLA to NPC de-
velopment. In this study, HLA-A expression was found in
NPC tumors, and was positively correlated with the mem-
branal and cytoplasmic expression levels of Hsp70, which
are in agreement with previous studies [36,37]. Hsp70 fam-
ily members are known as facilitators of immune responses
by interacting with receptor on antigen-presenting cells
leading to Hsp70-peptide uptake and antigen cross priming
[38]. Moreover, As a chaperone, Hsp70 has the abilities to
induce strong antiviral T-cell responses [39] and to elicit
LMP2A-specific IFN-γ-producing cells and rousted cyto-
toxic T lymphocytes (CTLs) in vitro and in vivo [40]. Fur-
thermore, it has been shown that HSP70 significantly
increase MHC class I cell surface expression and antigen
presentation on melanoma B16 cells [41,42]. Therefore, the
membranal and cytoplasmic Hsp70 might play a role in the
HLA related immune response, so as to exhibit the anti-
tumor effect on NPC. Indeed, the application of Hsp70 for
cancer therapy as a tumor-antigen carrier has been exten-
sively investigated in cancers [22,43-47], including NPC
[23].
On the other hand, we found high Hsp70 abundance
in the nuclei in NPC tissues, which positively correlated
with tumor recurrence, distant metastasis and a poor
survival rate. Moreover, in NPC tumors with Hsp70
abundant in the nuclear, we found low abundance of
HLA-A, even though the correlation didn’t reach a sta-
tistically significance. These findings suggested that nu-
cleic localization of Hsp70 might decrease HLA-A cell
surface expression and antigen presentation, and play
tumorigenic role in NPC. This is supported by previous
report that Hsp70 can effectively inhibit tumor cell death
induced by several stresses such as heat shock, hypoxia
and oxidative stress [48]. Moreover, studies have shown
that Hsp70 can translocate from cytoplasm to nucleus
or nucleoli under heat-stress conditions and plays a pro-
tective role against stress-mediated apoptosis and DNA
damage by co-localizing with DNA repair proteins,
[49,50], and thus increases tumor cell survival.Conclusion
Here, we described the distinct expression patterns of
Hsp70 in human NPC tissues, which might play different
roles during NPC tumor cell progression, could predict
different patient outcomes for the first time. Furthermore,
our data suggest that the different localization of Hsp70
could be molecular targets for the development of novel
therapeutic strategies.Additional files
Additional file 1: Figure S1. Association of Hsp70 membranal and
cytoplasmic expression levels with survival of NPC patients at different
Cai et al. Journal of Translational Medicine 2012, 10:96 Page 9 of 10
http://www.translational-medicine.com/content/10/1/96stages. A and B, no significant differences in five-year OS and DFS rates
were found between low and high levels of Hsp70 membranal and
cytoplasmic expression levels in NPC patients with early stage disease
(stage I - II). C and D, high Hsp70 membranal and cytoplasmic expression
levels were significantly positively associated with overall survival (OS,
P= 0.006) and disease-free survival (DFS, P= 0.007) in NPC patients with
late-stage disease (stage III-IV).
Additional file 2: Figure S2. Association of Hsp70 nuclear abundance
with survival of NPC patients at different stages. A and B, no significant
differences in five-year OS and DFS rates were found between low and
high levels of Hsp70 nuclear abundance in NPC patients with early stage
disease (stage I - II). C and D, high Hsp70 nuclear abundance were
significantly positively associated with the survival (OS, P= 0.006) and
disease-free survival (DFS, P= 0.007) in NPC patients with late-stage
disease (stage III-IV).
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